Viridian Therapeutics Price Target Cut to $36 from $40 at Truist
Truist lowered the company’s price target for Viridian Therapeutics (VRDN) to $36 from $40 and maintains a Buy rating on the stock as part of a broader research note previewing first-quarter earnings in biotech. Reactivity to regulatory and policy changes across the sector continues to decline, with the firm also seeing a recent rebound in…